posted
it isn't doing much but I have a piece of it. They were planning a close on a deal 14 Nov. waiting to see if it happened. Here is the site news page
Vera Leonard CEO/President/Director CLX Medical, Incorporated Murrieta , CA Sector: HEALTHCARE / Medical Instruments & Supplies Officer since November 2007
63 Years Old On September 15, 2008, the Board of Directors appointed Vera Leonard, Chief Executive Officer and President of the Company, to the Board of Directors effective September 15, 2008. Ms. Leonard, age 63, has considerable successful experience in leadership positions with major medical manufacturing and distribution companies. From 1999 to 2003 Ms. Leonard served as vice president of U.S. sales for Quidel Corporation, a Nasdaq listed company that specializes in rapid, point-of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately $8 million in annual revenue and helped to grow revenues from $32 million to $51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than $1,500,000 annually for the company from renegotiations of growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees. From 2004 to 2005 Ms. Leonard served as director of vendor relations for Henry Schein, Inc., a Fortune 500 distributor of medical and dental supplies to office-based practices worldwide. In this position, she launched 6 new products; negotiated semi-exclusive distribution rights on three innovative new products; designed a product launch template that was adopted for standard use by the entire medical marketing team; negotiated an exclusive special pricing agreement on market-leading product to maximize competitive conversions; and completed an in-depth pricing analysis by vendor, sales division and SKU to assess pricing strategies and assure competitive positioning while maximizing profitability. From 2005 to 2007 Ms. Leonard served as President of Vera Leonard, Inc., an alliance that provides business consulting, leadership development, sales training and executive coaching to individuals and corporations. Under Ms. Leonard"s leadership, her company received awards for outstanding sales performance and distribution partnering from industry-leading distributors 3 years in a row and 4 years total. She restructured the sales and support organization to establish standards of performance, goal-driven compensation plan, territory-level budget and forecast management while developing individuals for promotion to levels of greater responsibility and leadership. Previous to these positions, Ms. Leonard served as sales representative, sales manager, regional sales manager, and national sales manager for medical manufacturing and distribution companies where she developed an extensive firsthand knowledge of the medical supply field. These companies ranged from start-ups to major U.S. and international firms.
Posts: 22 | Registered: Dec 2005
| IP: Logged |
posted
Press Release Source: CLX Medical, Inc. CLX Medical, Inc. Announces Close of ThyroTest® Acquisition Issued Monday December 2, 8:50 am ET MURRIETA, CA--(MARKET WIRE)--Dec. 2, 2008--CLX Medical, Inc. (OTC BB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced the close of the company’s acquisition of ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. With the close of the transaction, CLX Medical will implement its ThyroTest® marketing program and establish distribution of the product with a national U.S. distributor. ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors’ offices in the U.S., as well as in any non-waived laboratory. Vera Leonard, CEO of CLX Medical, stated, “We have already begun the planning and laid the groundwork for our ThyroTest® marketing efforts, and the close of the acquisition frees us up to take the next steps in the process.” To close the transaction, an escrow was established, into which the ThyroTest® technology, the $750,000 note and the 750,000 shares of Series C Preferred Shares were deposited. CLX Medical entered into a definitive agreement with ThyroTec, LLC, the developer of the ThyroTest® device, on September 8, 2008 and subsequently entered into an amendment to the definitive agreement. The amendment provided that the transaction could be closed through the issuance to ThyroTec of Series C Convertible Preferred Shares of CLX Medical and a note in the amount of $750,000 at 6% interest for a term of 30 months, secured by the assets of the corporation. During the period of the note or until the principal is paid in full, CLX agrees to pay to ThyroTec a royalty of 10% of net sales of the ThyroTest® product.
-------------------- Its All About the Green Backs Baby$$$$$ Posts: 46 | From: Fort Hood, Texas | Registered: Nov 2008
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
